ZYDUSLIFE
PharmaceuticalsZydus Lifesciences Limited
Zydus Life is a subsidiary of Zydus Wellness Limited, which is an Indian consumer healthcare company. It was founded in 1985 and has its headquarters in Ahmedabad, India. Over the years, Zydus Life has expanded its product portfolio to include a range of consumer healthcare products, including personal care and over-the-counter products.
The company has seen steady growth over the years and has a strong presence in the Indian consumer healthcare market. As of 2021, Zydus Life's revenue was reported to be around Rs 2,404 crore and its net profit was reported to be around Rs 201 crore.
Zydus Life's product portfolio is diversified and includes categories such as skin care, oral care, wellness, and other personal care products. Some of its popular brands include Nutralite, SugarFree, Everyuth Naturals, and Rajdhani.
The company's future growth is expected to be driven by factors such as the growing awareness about personal health and wellness in India, increasing disposable income, and the increasing penetration of organized retail.
In terms of industry analysis, the consumer healthcare industry in India is highly competitive and characterized by the presence of several large multinational corporations as well as local players. Some of Zydus Life's direct competitors include Hindustan Unilever, Johnson & Johnson, and Procter & Gamble.
- Trades at a P/E of 30, with a return on equity (ROE) of 20.7%.
- ZYDUSLIFE is trading above 3 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bullish technical setup.
- Year-to-date it is up 22.79%, and up 19.49% over the past year.
- At ₹1,108.70 it sits about 79% of the way up its 52-week range (₹835.50–₹1,181.50).
- Offers a dividend yield of 0.26%.
- Market capitalisation stands at ₹1.12L Cr.
Shareholding data syncs daily.
| Year | Revenue | Net Profit | EPS | NPM |
|---|---|---|---|---|
| Mar 2023 | ₹8,732 Cr | ₹1,529 Cr | ₹15.11 | 17.51% |
| Mar 2022 | ₹7,982 Cr | ₹858 Cr | ₹8.38 | 10.75% |
| Mar 2021 | ₹7,790 Cr | ₹1,476 Cr | ₹14.42 | 18.95% |
| Mar 2020 | ₹6,347 Cr | ₹1,413 Cr | ₹13.80 | 22.26% |
| Mar 2019 | ₹6,037 Cr | ₹1,486 Cr | ₹14.51 | 24.61% |
| Mar 2018 | ₹5,810 Cr | ₹1,091 Cr | ₹10.66 | 18.78% |
| Mar 2017 | ₹3,231 Cr | ₹662 Cr | ₹6.47 | 20.49% |
| Mar 2016 | ₹7,032 Cr | ₹2,038 Cr | ₹19.90 | 28.98% |
| Mar 2015 | ₹5,284 Cr | ₹1,271 Cr | ₹12.42 | 24.05% |
| Mar 2014 | ₹4,042 Cr | ₹904 Cr | ₹8.83 | 22.37% |
| Mar 2013 | ₹3,527 Cr | ₹499 Cr | ₹4.87 | 14.15% |
| Mar 2012 | ₹3,151 Cr | ₹658 Cr | ₹6.42 | 20.88% |
| Company | P/E | Book Value | Sales Growth |
|---|---|---|---|
| SUNPHARMA SUN PHARMACEUTICAL INDUSTRIES LTD. | 39.1 | ₹98.33 | 10.1% |
| MARKSANS MARKSANS PHARMA LTD. | 23.8 | ₹11.85 | 5.8% |
| MOREPENLAB MOREPEN LABORATORIES LTD. | 20.81 | ₹6.43 | 16.6% |
| NEULANDLAB NEULAND LABORATORIES LTD. | 23.48 | ₹542.16 | 9.35% |
| GUFICBIO Gufic BioSciences Ltd. | 24.16 | ₹10.85 | 20.41% |
| DIVISLAB DIVI'S LABORATORIES LTD. | 41.01 | ₹266.77 | 9.47% |
| DRREDDY DR.REDDY'S LABORATORIES LTD. | 19.73 | ₹852.69 | 1.07% |
| RPGLIFE RPG LIFE SCIENCES LTD. | 17.14 | ₹105.02 | 5.73% |
| GLAND Gland Pharma Ltd | 53.6 | ₹242.00 | — |
| SMSPHARMA SMS PHARMACEUTICALS LTD. | 9.58 | ₹42.07 | -8.73% |
| CIPLA CIPLA LTD. | 15.36 | ₹209.71 | 0.7% |
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 08 Mar 2006 | DEUTSCHE SECURITIES MAURI | SALE | 3,27,475 | ₹565.56 |
| 16 Apr 2004 | Carlson Fund | SALE | 5,00,000 | ₹536.07 |
| 16 Apr 2004 | Govt.of Singapore Investm | PURCHASE | 4,91,703 | ₹536.00 |
Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.